(Q38071124)

28 August 2017

1 reference

title

Monoclonal antibodies for asthma and chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

28 August 2017

main subject

1 reference

1 reference

Sabina Antonela Antoniu

series ordinal

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

3 January 2013

1 reference

Expert Opinion on Biological Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

257-268

1 reference

Associations of IL6 polymorphisms with lung function decline and COPD.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Epithelial, dendritic, and CD4(+) T cell regulation of and by reactive oxygen and nitrogen species in allergic sensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

IL-5- and eosinophil-mediated inflammation: from discovery to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Eosinophilic Inflammation in Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

21 January 2018

IL-5 and eosinophilia.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Anti-interleukin 5 strategies as a potential treatment for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Reslizumab for Poorly Controlled, Eosinophilic Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Cytokine antagonists for the treatment of asthma: progress to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

IL-4 induces IL-13-independent allergic airway inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

IL-13 as a therapeutic target for respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-beta1, TGF-beta2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on alpha-smooth muscle actin and collagen III synthesis by primary hu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Monoclonal antibodies for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Epithelial cell-derived IL-25, but not Th17 cell-derived IL-17 or IL-17F, is crucial for murine asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

IL-17A and IL-25: therapeutic targets for allergic and exacerbated asthmatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Effects of omalizumab on markers of inflammation in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Treatment of allergic asthma: modulation of Th2 cells and their responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Dynamic role of epithelium-derived cytokines in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Thymic stromal lymphopoietin (TSLP)-mediated dermal inflammation aggravates experimental asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

OX40/OX40 ligand interactions in T-cell regulation and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

21 January 2018

Bradykinin and asthma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

First study of infliximab treatment in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Anti-interleukin-17 antibodies attenuate airway inflammation in tobacco-smoke-exposed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

IL-18 induces emphysema and airway and vascular remodeling via IFN-γ, IL-17A, and IL-13

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758247

10.1517/14712598.2012.758247

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference